Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination

In the dose-escalation phase of a Phase I clinical trial in which six subjects each were vaccinated with PepCan at the 50, 100, 250, and 500 μg per peptide dose, the 50 μg dose showed the best histological regression rate. Ten additional subjects were vaccinated at this dose in the final dose phase....

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunol Immunother
Main Authors: Coleman, Hannah N., Greenfield, William W., Stratton, Shawna L., Vaughn, Rita, Kieber, Alexander, Moerman-Herzog, Andrea M., Spencer, Horace J., Hitt, Wilbur. C., Quick, Charles Matthew, Hutchins, Laura F., Mackintosh, Samuel G., Edmondson, Ricky D., Erickson, Stephen W., Nakagawa, Mayumi
Format: Artigo
Language:Inglês
Published: Springer Berlin Heidelberg 2016
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841729/
https://ncbi.nlm.nih.gov/pubmed/26980480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1821-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items